Tscan Therapeutics is trading 7.4% down at $0.18, with no direct explanation reported. - Searches found no October 30 company announcement or reliable report explaining the decline; latest identified company news was an October 28 manufacturing collaboration, not an established cause. - Coverage described biotechnology shares rising that day; sector weakness does not appear to explain the drop. - Several weak sessions preceded the decline, but supplied price history alone offers no catalyst; confidence is low.